90 day money-back guarantee
Lab order in minutes
Save a trip to the doctor
Low prices since 2005
Labs within 2 miles
Private, accurate & secure
90 day money-back guarantee
Lab order in minutes
Save a trip to the doctor
Low prices since 2005
Labs within 2 miles
Private, accurate & secure
Private MD Labs logo
Always private
Need help? Text 754-799-7833

Find the tumor marker option that fits your reason

Each of these answers a different question about which markers you want followed.

Loading…

Tumor marker blood tests measure substances such as AFP, CA 125, CA 19-9, CEA, PSA, CA 15-3, and CA 27.29. People compare them when they want to discuss a personal or family history, follow results already being watched, or understand which measurements relate to a particular concern. These results do not diagnose cancer on their own; noncancerous conditions and normal biological variation also influence them. Start by deciding whether you need one marker, a sex-specific panel, a breast-focused profile, or a monitoring panel that also reports blood counts, chemistry values, and inflammation-related results.

What tumor markers measure—and what they do not establish

AFP, CA 125, CA 15-3, CA 19-9, CA 27.29, CEA, PSA, and beta-2 microglobulin are blood measurements used in different screening conversations and monitoring plans. Their value often lies in comparing results over time alongside symptoms, imaging, examination findings, and medical history. A higher or lower result does not establish that cancer is present or absent. For example, CEA and CA 19-9 are included together in several options, while CA 125 appears in female-oriented panels and total PSA appears in male-oriented panels. A clinician can explain whether a result, trend, or combination warrants follow-up.

Why blood counts and chemistry results are included in monitoring panels

Tumor Monitoring Insights pairs AFP, CA 19-9, and CEA with a complete blood count, comprehensive chemistry measurements, GGT, LD, sedimentation rate, and high-sensitivity CRP. Blood counts report red cells, hemoglobin, white cells, and platelets; these findings help describe anemia or changes in blood-cell patterns. Chemistry measurements include ALT, AST, alkaline phosphatase, bilirubin, albumin, creatinine, and eGFR, which relate to liver enzymes, proteins, and kidney filtration. AST and ALT can rise after strenuous exercise or for reasons unrelated to cancer, while creatinine varies with muscle mass. Looking at related results helps prevent overreading one value.

Cancer Screening & Monitoring FAQ

A tumor marker blood test measures substances such as AFP, CA 125, CA 19-9, CEA, PSA, or CA 27.29 that may be relevant to screening discussions or monitoring. The result is not a standalone cancer diagnosis. Professionals interpret it with your history, symptoms, physical findings, imaging, and prior results, especially when assessing a change over time.

The Tumor Marker Panel for Females measures AFP, beta-2 microglobulin, CA 125, CA 15-3, CA 19-9, and CEA. CA 125 distinguishes it from the male panel, while CA 15-3 adds a breast-associated marker. The panel does not include PSA, which is included in the male-oriented option.

The Tumor Marker Panel for Males measures AFP, beta-2 microglobulin, CA 19-9, CEA, and total PSA. The female panel instead includes CA 125 and CA 15-3. This difference matters when a discussion centers on PSA versus CA 125 or CA 15-3, rather than simply seeking the largest number of measurements.

The Breast Cancer Profile measures CA 27.29, CA 15-3, and CEA, making it a concentrated choice for conversations involving those three markers. It does not measure CA 125, CA 19-9, AFP, or PSA. Like other marker tests, it supports monitoring or clinical evaluation and does not confirm or rule out cancer by itself.

CEA and CA 19-9 appear together in the Colorectal & Colon Cancer Blood Scan, Basic Cancer Monitoring Scan, and Tumor Monitoring Insights. Measuring both creates two reference points for a clinician to consider alongside other findings and prior values. Neither marker is specific enough to diagnose cancer, and changes can have causes outside cancer.

Tumor Monitoring Insights measures AFP, CA 19-9, CEA, GGT, LD, sedimentation rate, high-sensitivity CRP, blood counts, and chemistry values including ALT, AST, bilirubin, creatinine, and eGFR. Hemoglobin and red-cell results help assess anemia patterns, while liver enzymes and bilirubin help frame liver-related findings. These related measurements add information beyond tumor markers alone.

No. A normal tumor marker result does not rule out cancer because not every cancer produces a measurable rise in a given marker, and marker levels vary among individuals. Conversely, an elevated value does not diagnose cancer. Persistent symptoms or concerning changes deserve professional evaluation regardless of a single blood result.

Yes. Alpha-Fetoprotein (AFP), Serum, Tumor Marker measures AFP alone, whereas the female and male tumor marker panels combine AFP with several other markers. An AFP-only result fits a specific request to follow AFP. A panel supplies additional values such as CEA, CA 19-9, CA 125, or PSA for a broader clinical discussion.

Yes. CA 125 with HAMA Treatment measures CA 125 without the other markers in the Tumor Marker Panel for Females. CA 125 can be relevant to an ovarian-cancer evaluation or monitoring plan, but it cannot diagnose or rule out ovarian cancer by itself. Noncancerous conditions can also affect the result, so review it with a qualified healthcare professional.

Ordering & Results FAQ

You'll receive it via email within 60 seconds of your order unless it requires additional processing (only very complex orders do).

Many general wellness test results are typically available online within 2-3 business days. However, some tests will require additional processing time. You will immediately receive an email & SMS notification when your results are available.

We do not share your results with your physician, insurance company, or any other third party.

Blood test labs by state

A C D F G I K L M N O P S T U V W